One biotech name is tighter to support than it's been all month

What the system saw

CRNX sits in the 97th percentile for relative strength over the last 63 days — and this morning it barely dipped below the 20-day moving average before climbing right back above it. We're talking about a stock that's outperforming nearly everything else in the market, and it just handed us a second entry. The Relative Strength Engine scored it 72.3 out of 100 and flagged it. We already had a day-six position in CRNX running a modest +0.3%. Now we've added a second look at the same name from a slightly different angle.

Why our Relative Strength Engine liked it

The core idea is simple: strong stocks stay strong. When a name in the top decile of relative strength pulls back to its 20-day moving average and holds — or barely dips and immediately reclaims it — that's the kind of tight, controlled reset that tends to precede the next leg higher. Today's low was $84.20. The 20-day sits at $83.84. The stock closed the prior session at $84.15 and is trading at $84.22 right now. It didn't break. It touched and bounced. That's exactly what we want to see. The fundamentals aren't the story here — negative earnings, negative ROE, and a DCF that doesn't say much for a clinical-stage biotech. The analyst consensus is Buy with an average target of $84.86, which lands right on top of where we're currently trading. This is a purely technical, momentum-driven setup. The system isn't buying the balance sheet. It's buying the behavior.

The trade plan

The Relative Strength Engine entered at $84.22 with a stop at $83.46 — that's $0.76 of risk per share. The 2R target sits at $85.73. We're putting about $5,053 behind it (60 shares) in the paper account. The math is clean: hit the target, and we make roughly $1.51 per share; hit the stop, and we lose $0.76. That's the 2-to-1 structure the system targets on every trade. CRNX is now our second open position in this name simultaneously — worth keeping in mind as you read the next section.

Position size: our paper account is putting about $5,053 (60 shares) into this trade, sized to risk roughly $46 if our stop is hit. This is what the system committed in its paper account — not a suggestion of how much you should put into any trade.

What could go wrong

A few things to hold in your head on this one. First, CRNX is already in the portfolio — day six, essentially flat. Adding a second position concentrates us in the same name, so if CRNX rolls over, it stings twice. Second, the stop at $83.46 is tight. A broad market wobble or any biotech-specific headline could take it out fast. SPY is barely moving today, up 0.01%, so there's no tailwind to lean on. Third, the Piotroski F-Score is 2 out of 9 — a weak fundamental profile by any measure. This isn't a name we'd hold for years. We're here for the technical setup and nothing else.

One more thought before we go

We're now at day 26 of tracking this system publicly. The overall account is up 5.9% against SPY's 2.9% in the same window. SNOW, CORT, and PIII are all running well in open positions. The win rate on closed trades is still 0-for-5 — and that's the number that should keep everyone honest. The open positions are carrying this thing right now, and none of them have closed yet. CRNX re-entering today either means the system sees something worth pressing harder — or it's about to show us exactly where a stop-loss earns its keep.